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ABSTRACT The clinical triad of pyoderma gangrenosum (PG), acne and 
suppurative hidradenitis (HS) has been described under the acronym 
PASH syndrome and is considered to represent a distinct entity in the 
group of autoinflammatory diseases. It is a fairly new, only recently rec-
ognized disorder with a limited number of reported cases and without 
defined treatment recommendations. We aimed to summarize current-
ly available data on the use of tumor necrosis factor (TNF) antagonists 
in the management of PASH syndrome and report on our own expe-
rience with the use of adalimumab in a patient presenting with this 
specific constellation of clinical signs and symptoms. Among the 11 
cases identified in the literature, infliximab and adalimumab were the 
most commonly used agents, both exhibiting favorable effects in the 
majority of, but not all, patients. This was particularly evident in terms 
of relatively rapid remission of PG whereas HS lesions seemed to be 
more resistant to treatment. In our patient, adalimumab monotherapy 
resulted in a remarkable and sustained remission, although significant 
improvement of HS lesions was observed only from week 16 of therapy 
onwards. In summary, TNF antagonists are a promising treatment for 
PASH; however, conclusions regarding the choice of a specific agent, 
optimal dosing or use in combination with other treatment modalities 
cannot yet be drawn. 
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INTRODUCTION
Clinically characterized by a triad of pyoderma 
gangrenosum (PG), acne and hidradenitis suppu-
rativa (HS), PASH is a relatively recently described 
syndrome placed within the spectrum of autoinflam-
matory diseases (1,2). Only a limited number of PASH 
cases has been reported in the literature and there 
are no well-established treatment modalities for this 
rare disorder. The impact this syndrome has on the 
patient’s life is profound and traditional treatment 
options have not demonstrated significant efficacy 
in terms of decreasing disease severity nor achiev-
ing sustained remission. We herein report a case of a 
male patient with a typical HS, new-onset of PG and 
previous history of remittent severe acne, in whom 
adalimumab monotherapy resulted in a remark-
able clinical improvement. We also summarize the 
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available literature data on the use of adalimumab 
and other tumor necrosis factor (TNF) antagonists in 
the treatment of PASH. 
CASE REPORT
A 41-year-old male Caucasian patient presented 
with three distinctly different patterns of skin lesions. 
The axillary vaults, inguinal folds, perianal region and 
buttocks showcased clusters of chronic abscesses 
and sinuses draining seropurulent material, with as-
sociated scarring (Figure 1, a, b, c). According to the 
recently established consensus criteria, these features 
were characteristic for the diagnosis of HS and were 
further classified as Hurley stage III due to the exten-
sive involvement (3,4). On the lower extremities, there 
were inflamed, erythematous plaques comprising nu-
merous pinpoint pustules and small punched-out ul-
cers, indicating a diagnosis of PG (Fig. 1d). On the up-
per portion of the patient’s back, there were multiple 
open comedones and atrophic scars, consistent with a 
history of cystic acne throughout puberty (Fig. 1e). The 
patient first exhibited the signs of PG four years after 
the initial presentation of HS. His medical history also 
included a pilonidal sinus surgery 10 years prior to the 
development of the  clinical picture described above. 
Histopathology findings of incisional biopsies 
were consistent with HS and PG. Routine laboratory 
examinations were within normal reference values 
aside from an increase in C-reactive protein up to 
69.6 mg/L and slight iron-deficiency anemia. Lack 
of specific symptoms and further laboratory testing 
ruled out the diagnosis of inflammatory bowel dis-
ease and patient denied any symptoms suggestive 
of arthritis. Cultures taken from leg ulcers, the axillae 
and the inguinal folds disclosed methicillin-resistant 
Staphylococcus aureus, Pseudomonas aeruginosa and 
Proteus mirabilis, respectively, despite multiple previ-
ous treatments with systemic antibiotics.
Throughout the 4-year treatment period, various 
systemic therapies have been used in an attempt to 
control the disease activity. Initially, treatment with 
dapsone led to a partial remission, but the patient 
developed methemoglobinemia. A combination of 
clindamycin and rifampicin was then used to treat the 
HS lesions along with relatively high doses of predni-
sone to treat the PG ulcers, but only modest and tem-
porary improvement was achieved. Subsequently, 
an immunosuppressive regimen with prednisone 
and azathioprine resulted in decreased inflamma-
tion of HS lesions and partial resolution of PG ulcers 
into dusky, cribriform, scarring plaques. However, the 
refractory nature of the disease led to an overall un-
satisfactory control, and therefore, adalimumab was 
introduced into therapy. 
In accordance with the treatment scheme used by 
Miller et al. for the treatment of HS (5), we implement-
ed a regime with an induction dose of 160 mg subcu-
taneously (SC) as 4 injections of 40 mg on Day 0, fol-
lowed by 80 mg 2 weeks later, and a weekly mainte-
nance dose of 40 mg beginning at week 4. At week 6 
of the treatment, the patient presented with multiple 
pustules on the soles of both feet. A clinical diagnosis 
of plantar pustulosis was made and the condition was 
regarded as a side-effect of adalimumab, which was 
easily controlled with topical corticosteroid therapy. 
A review of treatment effectiveness was conducted 
at week 12, when a considerable improvement was 
evident, but the overall results were still not satis-
factory. Even though it has been reported that sig-
nificant clinical improvement in HS lesions should 
be expected by week 12 (5), we were prompted to 
further continue the treatment due to the number of 
inflammatory lesions still active. At week 16, a signifi-
cant improvement was noted, with the evolvement 
of HS lesions into scarring. The patient achieved a 
cumulative response score of 50% from the baseline 
which was evaluated by the Hidradenitis Suppura-
tiva Clinical Response indicating that a minimum of 
half of all active HS lesions were suppressed while 
no new abscesses and draining fistulas have formed 
(6). Furthermore, the ulcerating lesions on the lower 
extremities had almost completely receded, leaving 
residual hyperpigmentation. It should be noted that 
not only did the patient’s clinical picture improve 
since the introduction of adalimumab, but so did the 
quality of his life, with initial Dermatology Quality of 
Life Index (DLQI) score of 13 dropping to 4. This 9-
point improvement was much greater than the score 
change of 4 proposed as minimal clinically important 
difference of DLQI in inflammatory skin diseases (7). 
Therefore, even though the treatment did not lead to 
complete remission of the inflammatory activity, the 
improvement was substantial enough for the therapy 
to be continued. Throughout the maintenance peri-
od, additional benefit was observed, and at 6 months 
since the introduction of adalimumab there was only 
minimal residual erythema and post-inflammatory 
dyspigmentation (Figure 2). Therapy has continued 
since the initial dose and the patient did not experi-
ence any relapses or side effects throughout the fol-
lowing year. 
DISCUSSION
PASH syndrome was first described as an entity by 
Braun-Falco et al. in 2012 and is currently classified as 
an autoinflammatory disease (1,8). When compared 
to other recognized or only recently suggested syn-
dromes within the spectrum, such as PAPA (pyogenic 
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Reference Age, sex Comorbidities Treatment Outcome
Bruzzese (20) 33, M axial spondyloarthritis etanercept no improvement
infliximab complete remission 
Garzorz et al. 
(18)
39, F psoriasis, seronegative 
arthritis
adalimumab fairly stable disease control




Marzano et al. 
(2,9)
34, M bowel bypass surgery 
for morbid obesity
infliximab (5mg/kg) at 
weeks 0, 2 and 6 and every 
8-12 weeks thereafter
almost complete healing of PG 
and acne lesions with only mild 
HS disease activity in the perianal 
area, partial remission under 
maintenance schedule
Marzano et al. 
(9)
45, F cervicobrachial pain infliximab (5 mg/kg) at 
weeks 0, 2 and 6 and every 
8-12 weeks thereafter
almost complete healing of PG 
and acne lesions with only mild 
HS disease activity in the perianal 
area, partial remission under 
maintenance schedule
43, M spondyloarthritis, 
osteitis
infliximab (5mg/kg) at week 
0, 2 and 6
remarkable improvement of PG, 
acne and spondyloarthritis but not 
of HS lesions
23, M Crohn's disease adalimumab 80 mg at week 
0 and 40 mg every 2 weeks 
thereafter
partial remission with good control 
of disease activity from week 4 
onwards 
Moschella (17) 36, F Crohn's disease infliximab (5mg/kg) at 
weeks 0, 2, 6 and 3 infusions 
every 8 weeks thereafter
significant improvement in both 
HS and PG lesions; remission 
maintained 4 months (at least) after 
discontinuing infliximab 
Murphy et al. 
(16)
26, F ulcerative colitis cyclosporine (250 mg 2×/
day) + prednisolone (20 mg/
day) + 2 doses of infliximab 
(5mg/kg) 
rapid improvement of skin 
lesions; treatment stopped after 
2nd dose due to probable drug 
hypersensitivity 
adalimumab induction dose 
(160 mg + 80 mg), followed 
by maintenance dose of 40 
mg every 2 weeks
marked improvement within 2 
months, maintained remission with 
additional healing thereafter
Saraceno et al. 
(19)






adalimumab (40 mg every 
other week)
remission of HS and PG lesions after 
4 weeks of treatment, maintained 
effect over the 36 weeks of 
treatment
Staub et al. (15) 22, F - systemic corticosteroids + 
etanercept for 10 months 
no (or only temporary) 
improvement
systemic corticosteroids + 
dapsone + adalimumab for 
5 months
no (or only temporary) 
improvement
infliximab (5 mg/kg) + 
dapsone + cyclosporine 
complete resolution of ulcerations 
in 4 months allowing taper of 
corticosteroids, with mild relapse 
after temporary cessation of 
cyclosporine
Table 1. Reports of patients with PASH syndrome or related syndromic entities treated with TNF antagonists 
Saint-Georges et al. Acta Dermatovenerol Croat
TNF antagonists for PASH syndrome   2018;26(2):173-178
176 ACTA DERMATOVENEROLOGICA CROATICA
arthritis, PG, acne), PAPASH (pyogenic arthritis, PG, 
acne, HS), PsAPASH (psoriatic arthritis, PG, acne, HS) 
and PASS (PG, acne, HS and seronegative spondylo-
arthritis), PASH sets itself apart by showing strong 
affinity towards the skin, while lacking the presence 
of arthritis, one of the hallmark features of all afore-
mentioned entities (1,8). While mutations in the 
gene encoding the proline-serine-threonine-phos-
phatase-interacting protein 1 (PSTPIP1) have been 
found specifically in PAPA and PAPASH patients, PASH 
patients can have a wide array of genetic alterations 
typically occurring in different autoinflammatory dis-
eases (1,8,9). Suggested pathophysiology common 
to this whole group of diseases includes hyperacti-
vated innate inflammatory response with increased 
interleukin-1 beta and TNF-alpha signaling, as well 
as consequent recruitment and activation of neutro-
phils (9,10).
Even though we did not perform genetic testing 
in our patient, PASH syndrome was diagnosed based 
on distinct constellation of clinical findings. It is in-
teresting to note that Hsaio et al. have determined a 
consistent temporal relationship of PG occurring after 
the onset of HS (11). The authors suggested that PG 
is a cutaneous late-onset manifestation of the same 
underlying inflammatory process that was initially 
responsible for triggering HS (11). Their hypothesis is 
further supported by findings in our patient, since he 
disclosed a 10-year history of HS, but a only 4 years of 
PG prior to the first admission to our Department.
One of the traditional therapeutic options for both 
HS and PG is dapsone because of its power to sup-
press neutrophil recruitment (12,13). However, devel-
opment of methemoglobinemia oftentimes limits its 
use, as was the case in our patient. Currently, corti-
costeroids and cyclosporine are considered excellent 
choices for the initial therapy of PG due to the rapid 
onset of action, which could be followed by dapsone, 
azathioprine, mycophenolate mofetil and oral tacro-
limus (13). Recently, the often observed therapeutic 
failures of traditional systemic drugs explain the shift 
towards biologics, so that there are even suggestions 
that this group of drugs should be considered as 
the first line of treatment for PG (5,13,14). Still, even 
though adalimumab has been recently approved for 
the treatment of moderate to severe HS, both by the 
European Commission and the US Food and Drug 
Administration, the current use of TNF antagonists in 
the treatment of PG is considered off-label. 
When considering biologics for PASH, the most of-
ten utilized agents thus far have been either TNF an-
tagonists (summarized in Table 1) or the IL-1 receptor 
antagonist anakinra (1,2,9,11,15-20). Etanercept was 
employed in 2 patients and didn’t show any effect. 
Figure 1. Clinical presentation at baseline. Active HS lesions in (a) the right axilla, (b) the right ingvinal, (c) perineal and 
gluteal regions, (d) PG lesions on the left lower leg comprised of multiple pustules and punched out ulcers and (e) open 
comedones and depressed scars as sequelae from severe pubertal acne. 
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Infliximab was used in 8 and adalimumab in 7 cases, 
including our patient, with comparable success rate. 
Both drugs showed encouraging results, with adali-
mumab displaying a slightly more consistent effect 
regarding remission of HS lesions (Table 1). In our 
patient, we chose a fully humanized anti-TNF agent 
due to the lower potential for the development of 
anti-drug antibodies that could ultimately lead to 
loss of efficacy, less common adverse effects such as 
antibody-mediated infusion reactions and the con-
venience of self-administered SC injections. While 
implementing the HS treatment scheme provided 
by Miller et al., our patient did not show the satisfac-
tory control of inflammation in HS lesions by week 
12 as was expected (5). However, similarly to the re-
sults published by Kimball et al. (21), a significant im-
provement was reached after an additional 4 weeks 
of treatment, indicating that the treatment should be 
continued past week 12. 
CONClUSION
The use of TNF antagonists has shown to be a 
promising treatment for patients with PASH syn-
drome and related syndromic entities. It seems that 
significant clinical response in HS lesions occurs in 
a delayed manner and judgment of treatment fail-
ure for a given drug should not be made too hastily. 
However, controlled clinical trials are necessary to 
adequately evaluate the efficacy of TNF antagonists 
in patients with this rare syndrome and to allow con-
clusions regarding the optimal treatment regimens 
necessary for long-term disease control.
Source of support: Adalimumab was supplied as a do-
nation by AbbVie. 
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